TY - JOUR
T1 - Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH
AU - Roberts, Rosebud O.
AU - Bergstralh, Erik J.
AU - Farmer, Sara A.
AU - Jacobson, Debra J.
AU - McGree, Michaela E.
AU - Hebbring, Scott J.
AU - Cunningham, Julie M.
AU - Anderson, Sarah A.
AU - Thibodeau, Stephen N.
AU - Lieber, Michael M.
AU - Jacobsen, Steven J.
PY - 2005/3/1
Y1 - 2005/3/1
N2 - BACKGROUND. The objective of the study was to examine associations between SRD5A2 polymorphisms and measures of benign prostatic hyperplasia (BPH). METHODS. Participants were 510 Caucasian men (median age 60 years), randomly selected from the Olmsted County, MN community to participate in a longitudinal study of BPH. From 1990 through 2000, biennial measurements of lower urinary tract symptom severity (assessed from the American Urological Association Symptom Index, AUASI), peak urinary flow rates (Qmax), and prostate volume were made. Genotyping of SRD5A2 V89L, A49T, and TA repeat polymorphisms were performed. RESULTS. Compared with the VV genotype, the LL genotype was associated with an enlarged prostate (Hazard ratio (HR) = 1.62, 95% confidence interval (CI) = 1.06, 2.43) but not with AUASI, Qmax, or PSA. The A49T and TA repeat polymorphisms were not associated with BPH. When the LL/VL, AT/TT, and TA(0)/TA(0) genotypes were considered high risk, the number of high risk genotypes increased with increasing prostate volume (32.3, 30.7, 34.1, and 38.7, respectively, P for trend = 0.04). CONCLUSIONS. These findings do not demonstrate consistent associations between SRD5A2 genotypes and BPH. However, they suggest that the associations of V89L polymorphisms and prostate volume should be investigated further.
AB - BACKGROUND. The objective of the study was to examine associations between SRD5A2 polymorphisms and measures of benign prostatic hyperplasia (BPH). METHODS. Participants were 510 Caucasian men (median age 60 years), randomly selected from the Olmsted County, MN community to participate in a longitudinal study of BPH. From 1990 through 2000, biennial measurements of lower urinary tract symptom severity (assessed from the American Urological Association Symptom Index, AUASI), peak urinary flow rates (Qmax), and prostate volume were made. Genotyping of SRD5A2 V89L, A49T, and TA repeat polymorphisms were performed. RESULTS. Compared with the VV genotype, the LL genotype was associated with an enlarged prostate (Hazard ratio (HR) = 1.62, 95% confidence interval (CI) = 1.06, 2.43) but not with AUASI, Qmax, or PSA. The A49T and TA repeat polymorphisms were not associated with BPH. When the LL/VL, AT/TT, and TA(0)/TA(0) genotypes were considered high risk, the number of high risk genotypes increased with increasing prostate volume (32.3, 30.7, 34.1, and 38.7, respectively, P for trend = 0.04). CONCLUSIONS. These findings do not demonstrate consistent associations between SRD5A2 genotypes and BPH. However, they suggest that the associations of V89L polymorphisms and prostate volume should be investigated further.
KW - Androgen
KW - Cohort studies
KW - Polymorphisms (genetics)
KW - Prostate
KW - Prostatic hyperplasia
KW - Risk factors
KW - Signs and symptoms
UR - http://www.scopus.com/inward/record.url?scp=13544264767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13544264767&partnerID=8YFLogxK
U2 - 10.1002/pros.20142
DO - 10.1002/pros.20142
M3 - Article
C2 - 15389785
AN - SCOPUS:13544264767
SN - 0270-4137
VL - 62
SP - 380
EP - 387
JO - Prostate
JF - Prostate
IS - 4
ER -